» Articles » PMID: 36646885

The Methylome and Cell-free DNA: Current Applications in Medicine and Pediatric Disease

Overview
Journal Pediatr Res
Specialties Biology
Pediatrics
Date 2023 Jan 16
PMID 36646885
Authors
Affiliations
Soon will be listed here.
Abstract

DNA methylation is an epigenetic mechanism that contributes to cell regulation and development, and different methylation patterns allow for the identification of cell and tissue type. Cell-free DNA (cfDNA) is composed of small circulating fragments of DNA found in plasma and urine. Total cfDNA levels correlate with the presence of inflammation and tissue injury in a variety of disease states. Unfortunately, the utility of cfDNA is limited by its lack of tissue or cell-type specificity. However, methylome analysis of cfDNA allows the identification of the tissue or cell type from which cfDNA originated. Thus, methylation patterns in cfDNA from tissues isolated from direct study may provide windows into health and disease states, thereby serving as a "liquid biopsy". This review will discuss methylation and its role in establishing cellular identity, cfDNA as a biomarker and its pathophysiologic role in the inflammatory process, and the ways cfDNA and methylomics can be jointly applied in medicine. IMPACT: Cell-free DNA (cfDNA) is increasingly being used as a noninvasive diagnostic and disease-monitoring tool in pediatric medicine. However, the lack of specificity of cfDNA limits its utility. Identification of cell type-specific methylation signatures can help overcome the limited specificity of cfDNA. As knowledge of the cfDNA methylome improves, cfDNA will be more broadly applied in medicine, such that clinicians will need to understand the methods and applications of its use.

Citing Articles

LINE-1 cfDNA Methylation as an Emerging Biomarker in Solid Cancers.

Gezer U, Ozgur E, Yoruker E, Polatoglou E, Holdenrieder S, Bronkhorst A Cancers (Basel). 2024; 16(22).

PMID: 39594682 PMC: 11592170. DOI: 10.3390/cancers16223725.


Response of Circulating Free Cellular DNA to Repeated Exercise in Men with Type 1 Diabetes Mellitus.

Walczak K, Grzybowska-Adamowicz J, Stawski R, Brzezinska O, Zmyslowska A, Nowak D J Clin Med. 2024; 13(19).

PMID: 39407919 PMC: 11477321. DOI: 10.3390/jcm13195859.


The Role of ctDNA and Liquid Biopsy in the Diagnosis and Monitoring of Head and Neck Cancer: Towards Precision Medicine.

Nassar S, Suk A, Nguyen S, Adilbay D, Pang J, Nathan C Cancers (Basel). 2024; 16(18).

PMID: 39335101 PMC: 11430155. DOI: 10.3390/cancers16183129.


Nucleic Acids-Based Biomarkers for Alzheimer's Disease Diagnosis and Novel Molecules to Treat the Disease.

Bivona G, Sammataro S, Ghersi G Int J Mol Sci. 2024; 25(14).

PMID: 39063135 PMC: 11277093. DOI: 10.3390/ijms25147893.


Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods.

Gromek P, Senkowska Z, Pluciennik E, Pasieka Z, Zhao L, Gielecinska A World J Methodol. 2024; 14(2):92982.

PMID: 38983668 PMC: 11229876. DOI: 10.5662/wjm.v14.i2.92982.


References
1.
Bergman Y, Cedar H . DNA methylation dynamics in health and disease. Nat Struct Mol Biol. 2013; 20(3):274-81. DOI: 10.1038/nsmb.2518. View

2.
Domcke S, Bardet A, Ginno P, Hartl D, Burger L, Schubeler D . Competition between DNA methylation and transcription factors determines binding of NRF1. Nature. 2015; 528(7583):575-9. DOI: 10.1038/nature16462. View

3.
Dor Y, Cedar H . Principles of DNA methylation and their implications for biology and medicine. Lancet. 2018; 392(10149):777-786. DOI: 10.1016/S0140-6736(18)31268-6. View

4.
Straussman R, Nejman D, Roberts D, Steinfeld I, Blum B, Benvenisty N . Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol. 2009; 16(5):564-71. DOI: 10.1038/nsmb.1594. View

5.
Hon G, Rajagopal N, Shen Y, McCleary D, Yue F, Dang M . Epigenetic memory at embryonic enhancers identified in DNA methylation maps from adult mouse tissues. Nat Genet. 2013; 45(10):1198-206. PMC: 4095776. DOI: 10.1038/ng.2746. View